ATV:TREM2 agonist antibody brain shuttle construct (ATV fused to anti-TREM2 agonist) achieves 50-fold higher brain exposure than unmodified antibody and shows superior microglial activation and plaque reduction in 5xFAD mice compared with anti-TREM2 alone, providing in vivo validation of the ATV platform for TREM2...

Evidence span

ATV:TREM2 agonist antibody brain shuttle construct (ATV fused to anti-TREM2 agonist) achieves 50-fold higher brain exposure than unmodified antibody and shows superior microglial activation and plaque reduction in 5xFAD mice compared with anti-TREM2 alone, providing in vivo validation of the ATV platform for TREM2...

From Guangxu Wei 1995, Neuron

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

source-reported model organism

Conditions

5xFAD mice; IV dosing with ATV:TREM2 vs anti-TREM2 alone; brain biodistribution by ELISA; microglial activation by scRNA-seq; amyloid PET and histology; ARIA-equivalent vascular assessment; n=10–15 per group.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required